Jim Cramer on Eli Lilly: "We're Not a Seller"

Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer offered insights on. Cramer discussed the future possibilities of the company’s weight loss drug, as he said:

“… Eli Lilly, which I think has beaten back Danish Novo Nordisk, maybe even into submission. After all, Lilly’s on the market with a very effective once-a-week shot, but more important, it’s soon going to have a pill version. It could be gigantic. People hate shots. No wonder Lilly’s stock vaulted nearly 5% today, on the verge of becoming… the first non-tech stock to cross into the $1 trillion circle besides Berkshire Hathaway. But I say not so fast. As much as I like Lilly for the Charitable Trust, where it’s a very big position and we’re not a seller, I’m mindful that you can’t take anything for granted in this business… Lilly’s spending a fortune to develop a pill form of the drug that you can take every day like any other medication, and that could be more popular than any shot. You’re much more likely to stick with a pill than an injection. Plus, one of the biggest drawbacks of the current GLP-1s is that they cause you to lose fat and muscle in equal measure. These drugs make you thin, but they make you weaker. However, Lilly’s working on a shot that’s more targeted. It will attack fat to muscle at a 3:1 ratio.”

Eli Lilly and Company (NYSE:LLY) develops pharmaceuticals for areas such as diabetes, obesity, oncology, immunology, and neuroscience.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.